Stifel Reiterates Buy Rating on Mirum Pharamceuticals (MIRM)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. HUBS
2. EXPE
3. ARM
4. BROS
5. FIS
6. DDOG
7. QCOM
8. EW
9. ZG
10. W

Go back to Stifel Reiterates Buy Rating on Mirum Pharamceuticals (MIRM)

Mirum’s Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies

June 17, 2024 8:00 AM EDT

- VANTAGE PBC interim analysis shows 3.8 point reduction from baseline and 2.3 point placebo-adjusted (p=0.0026) reduction in primary endpoint of pruritus

- VISTAS PSC interim analysis exceeds efficacy threshold for study continuation

- Mirum to host... More

Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024

June 16, 2024 5:00 PM EDT

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will host an investor call on Monday, June 17 at 8:30 a.m. ET to share interim analysis results from the Volixibat VANTAGE Phase 2b study in primary biliary cholangitis (PBC) and the Volixibat VISTAS Phase 2b study in primary sclerosing cholangitis (PSC).

Conference call details:

Monday June 17, 2024

8:30 a.m. ET / 5:30 a.m. PT

Dial-in:

U.S./Toll-Free: +1 833 470 1428

International: +1 404 975 4839

Passcode: 205511

You may also access the call via... More